Abstract:West Nile virus (WNV) is a neurotropic flavivirus that can cause significant neurological disease. Mouse models of WNV infection demonstrate that a proinflammatory environment is induced within the central nervous system (CNS) after WNV infection, leading to entry of activated peripheral immune cells. We utilized ex vivo spinal cord slice cultures (SCSC) to demonstrate that anti-inflammatory mechanisms may also play a role in WNV-induced pathology and/or recovery. Microglia are a type of macrophage that function as resident CNS immune cells. Similar to mouse models, infection of SCSC with WNV induces the upregulation of proinflammatory genes and proteins that are associated with microglial activation, including the microglial activation marker Iba1 and CC motif chemokines CCL2, CCL3, and CCL5. This suggests that microglia assume a proinflammatory phenotype in response to WNV infection similar to the proinflammatory (M1) activation that can be displayed by other macrophages. We now show that the WNV-induced expression of these and other proinflammatory genes was significantly decreased in the presence of minocycline, which has antineuroinflammatory properties, including the ability to inhibit proinflammatory microglial responses. Minocycline also caused a significant increase in the expression of anti-inflammatory genes associated with alternative anti-inflammatory (M2) macrophage activation, including interleukin 4 (IL-4), IL-13, and FIZZ1. Minocycline-dependent alterations to M1/M2 gene expression were associated with a significant increase in survival of neurons, microglia, and astrocytes in WNV-infected slices and markedly decreased levels of inducible nitric oxide synthase (iNOS). These results demonstrate that an anti-inflammatory environment induced by minocycline reduces viral cytotoxicity during WNV infection in ex vivo CNS tissue.IMPORTANCE West Nile virus (WNV) causes substantial morbidity and mortality, with no specific therapeutic treatments available. Antiviral inflammatory responses are a crucial component of WNV pathology, and understanding how they are regulated is important for tailoring effective treatments. Proinflammatory responses during WNV infection have been extensively studied, but anti-inflammatory responses (and their potential protective and reparative capabilities) following WNV infection have not been investigated. Minocycline induced the expression of genes associated with the anti-inflammatory (M2) activation of CNS macrophages (microglia) in WNV-infected SCSC while inhibiting the expression of genes associated with proinflammatory (M1) macrophage activation and was protective for multiple CNS cell types, indicating its potential use as a therapeutic reagent. This ex vivo culture system can uniquely address the ability of CNS parenchymal cells (neurons, astrocytes, and microglia) to respond to minocycline and to modulate the inflammatory environment and cytotoxicity in response to WNV infection without peripheral immune cell involvement.

Minocycline Modulates Neuroinflammation Independently of Its Antimicrobial Activity in Staphylococcus Aureus-Induced Brain Abscess

Minocycline Attenuates Brain Edema, Brain Atrophy and Neurological Deficits after Intracerebral Hemorrhage.

Minocycline Reduces Intracerebral Hemorrhage-Induced Brain Injury

Minocycline Protects Against NLRP3 Inflammasome-Induced Inflammation and P53-Associated Apoptosis in Early Brain Injury after Subarachnoid Hemorrhage

Minocycline mitigates sepsis-induced neuroinflammation and promotes recovery in male mice: Insights into neuroprotection and inflammatory modulation

Chronic Minocycline Treatment Exerts Antidepressant Effect, Inhibits Neuroinflammation, and Modulates Gut Microbiota in Mice

Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment in Mice

Minocycline enhances antimicrobial activity of unpolarized macrophages against Acinetobacter baumannii while reducing the inflammatory response

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration

Minocycline Suppresses NLRP3 Inflammasome Activation in Experimental Ischemic Stroke

Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis

Minocycline Ameliorates Lps-Induced Inflammation in Human Monocytes by Novel Mechanisms Including Lox-1, Nur77 and Litaf Inhibition

Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration

Minocycline Mitigated Enduring Neurological Consequences in the Mice Model of Sepsis

Minocycline Abrogates Individual Differences in Nerve Injury-Evoked Affective Disturbances in Male Rats and Prevents Associated Supraspinal Neuroinflammation

Minocycline reduces neuroinflammation but does not ameliorate neuron loss in a mouse model of neurodegeneration

Neuroprotection effect of minocycline on early brain injury after subarachnoid hemorrhage in rats

A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4

Minocycline Has Anti-inflammatory Effects and Reduces Cytotoxicity in an Ex Vivo Spinal Cord Slice Culture Model of West Nile Virus Infection

Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials

Attenuation of Acute Stroke Injury in Rat Brain by Minocycline Promotes Blood–brain Barrier Remodeling and Alternative Microglia/macrophage Activation During Recovery